Navigation Links
Enlarged prostate: Study demonstrates immediate and long-term benefits of laser treatment
Date:5/20/2011

This release is available in French.

New research presented at the Annual Meeting of the American Urology Association (AUA) in Washington, DC demonstrates that holmium laser therapy is a safe and durable treatment option for Benign Prostatic Hyperplasia (BPH) an enlargement of the prostate that affects most men as they age. The study, conducted by researchers from the McGill University Health Centre (MUHC), is the longest comprehensive assessment of this technology to date, and researchers suggest it may now safely be considered the new, size independent, gold standard for treatment of BPH.

A man's prostate naturally increases in size throughout life, but can occasionally reach a very large size placing pressure on the urethra and causing urination difficulties and bladder problems. A prostate of 40-60 grams is the average size for which corrective surgery is considered. Holmium laser therapy of the prostate, also known as Holmium Laser Enucleation of the Prostate (HoLEP) has been used since 1998 at the MUHC as an alternative treatment to surgery. This is particularly valuable for patients who have particularly large prostates and risk factors that render open surgery difficult.

"Treating small to moderate size prostates by regular Transurethral Resection of the prostate (TURP) a surgical technique that removes part of the prostate gland is still the chosen treatment for the majority of patients," explains Dr. Mostafa Elhilali, Stephen Jarislowsky Chair of Urology at McGill University, urologist at the MUHC and lead author of the new study. "However, the most challenging aspect about the use of minimally invasive techniques is the high rate of recurrence and the need for re-treatment over time."

The study, which looked at the durability of outcomes of HoLEP in nearly 1,000 patients over 10 years, demonstrated that complication rates are minimal and the need for further treatment, even up to a decade later, is less than 1 per cent, compared to 10-16 per cent with TURP. "Patients treated with HoLEP also have reduced pain and shorter hospital stays than those who undergo an open surgery," explains Dr. Elhilali. "They are often able to resume normal activities within a week and have few to no sexual side effects."

The researchers point out that HoLEP is more effective at adequately treating all sizes of prostatic enlargement, whereas other laser techniques, such as Green Light Laser, is effective on small to moderate size prostates, similar but not better than TURP and lacks the same long-term durability. Green Light Laser has been used at the MUHC since 2005. The results of a study comparing Green Light Laser in different sized prostates showed it to be less effective in treating larger prostates. This study was also presented at the AUA meeting yesterday.


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-934-1934 x71381
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Combination therapy more effective for enlarged prostate
2. Cholesterol-lowering drug shrinks enlarged prostates in hamster model
3. Doctors Issue New Guidelines on Spotting, Treating Enlarged Prostate
4. Apnea may be cause for awakening and voiding for those with enlarged prostates report Ben-Gurion U.
5. Stem Cell Therapy Shrinks Enlarged Hearts
6. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
7. Fewer Men Having Surgery to Treat Enlarged Prostate: Study
8. Heart-Healthy Omega-3s Not Healthy for Prostate: Study
9. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
10. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
11. TV drama can be more persuasive than news program, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Data Management Solution Providers list for its expertise in eClinical Solutions. DDi has ... to serve the technology needs of global clients. DDi provides smarter technology for ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted over 250 members of South Florida’s philanthropic community at its 10th anniversary ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... Pittsburgh, PA (PRWEB) , ... February 12, 2016 ... ... serving families of the Pittsburgh metro area, celebrates the beginning of the latest ... help children develop social skills through art. Donations to this worthy cause are ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., ... Implant System ® ("iFuse"), a minimally invasive surgical (MIS) device ... announced that National Government Services, Inc. (NGS), the Medicare Administrative Contractor ... Illinois , Maine , ... Hampshire , New York , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
Breaking Medicine Technology: